MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Novartis AG

Geschlossen

112.41 1.45

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

110.38

Max

114.32

Schlüsselkennzahlen

By Trading Economics

Einkommen

-369M

2.8B

Verkäufe

386M

14B

KGV

Branchendurchschnitt

18.992

63.778

EPS

1.98

Dividendenrendite

3.47

Gewinnspanne

20.8

Angestellte

75,883

EBITDA

-426M

5.2B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

-1.12% downside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.47%

2.39%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

6.9B

221B

Vorheriger Eröffnungskurs

110.96

Vorheriger Schlusskurs

112.41

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Novartis AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Feb. 2025, 06:57 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis to Buy Anthos Therapeutics for Up to $3.08 Billion

31. Jan. 2025, 09:49 UTC

Ergebnisse

Novartis Expects Further Profit, Sales Growth Despite Competition Threat -- 2nd Update

31. Jan. 2025, 08:06 UTC

Ergebnisse

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales -- Update

31. Jan. 2025, 06:32 UTC

Ergebnisse

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales

3. Apr. 2025, 20:15 UTC

Akquisitionen, Fusionen, Übernahmen

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3. Apr. 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

17. März 2025, 07:34 UTC

Market Talk

Novartis Growth Outlook Clouded by Patent Expiries, Pipeline Concerns -- Market Talk

4. März 2025, 18:45 UTC

Ergebnisse

Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction -- IBD

11. Feb. 2025, 09:25 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion -- Update

11. Feb. 2025, 06:42 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Novartis to Buy Anthos Therapeutics for Up to $3.08 Bln

11. Feb. 2025, 06:22 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis: Acquisition Is Aligned With Strategic Focus on Cardiovascular Therapeutic Area

11. Feb. 2025, 06:20 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis: Abelacimab's Lead Indication Is Prevention of Stroke, Systemic Embolism

11. Feb. 2025, 06:19 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis: Anthos Is Developing Abelacimab, Currently in Late-Stage Trials

11. Feb. 2025, 06:18 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis: Deal Is Expected to Close in 1H of 2025

11. Feb. 2025, 06:18 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis Aims to Bolster Late-Stage Cardiovascular Pipeline With Acquisition

11. Feb. 2025, 06:17 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis: Deal Includes Potential Additional Payments of Up to $2.15B

11. Feb. 2025, 06:16 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis to Buy Anthos Therapeutics for $925M Upfront

11. Feb. 2025, 06:15 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis to Buy Anthos Therapeutics

4. Feb. 2025, 15:16 UTC

Top News

Novartis Sets High Bar in Pursuit of Obesity Deals, CEO Says -- Interview

4. Feb. 2025, 08:12 UTC

Market Talk
Ergebnisse

Novartis Outlook Indicates No Patent Cliff Beyond 2025 -- Market Talk

31. Jan. 2025, 13:56 UTC

Ergebnisse

Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker -- IBD

31. Jan. 2025, 09:59 UTC

Heiße Aktien

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

31. Jan. 2025, 07:50 UTC

Market Talk

Novartis's Outlook Exceeds Market Views -- Market Talk

31. Jan. 2025, 07:46 UTC

Market Talk
Ergebnisse

Novartis's Results Beat Could Clear Gap Between Mid-Term Outlook and Market Views -- Market Talk

31. Jan. 2025, 06:03 UTC

Ergebnisse

Novartis Expects 2025 Core Operating Profit Growth of High Single to Low Double-Digit at Constant Currency

31. Jan. 2025, 06:02 UTC

Ergebnisse

Novartis Expects 2025 Net Sales Growth of mid- to high-single Digit at Constant Currency

31. Jan. 2025, 06:02 UTC

Ergebnisse

Novartis Issues 2025 View

31. Jan. 2025, 06:02 UTC

Ergebnisse

Novartis Raises Dividend to CHF3.50 Vs CHF3.30

31. Jan. 2025, 06:02 UTC

Ergebnisse

Novartis 4Q Oper Pft $3.53B

31. Jan. 2025, 06:02 UTC

Ergebnisse

Novartis 4Q Net Pft $2.82B

Peer-Vergleich

Kursveränderung

Novartis AG Prognose

Kursziel

By TipRanks

-1.12% Nachteil

12-Monats-Prognose

Durchschnitt 111 USD  -1.12%

Hoch 125 USD

Tief 97 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Novartis AG – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

2 ratings

0

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

112.09 / 112.57Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Strong Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.